TELEPRO: Patient‐Reported Carcinoid Syndrome Symptom Improvement Following Initiation of Telotristat Ethyl in the Real World

BACKGROUND. When carcinoid syndrome (CS) diarrhea (CSD) is inadequately controlled with long‐acting somatostatin analogs (SSAs), clinical practice guidelines recommend addition of the tryptophan hydroxylase inhibitor telotristat ethyl (TE). In a 12‐week multinational, randomized controlled trial, TE...

Descripción completa

Detalles Bibliográficos
Autores principales: Strosberg, Jonathan, Joish, Vijay N., Giacalone, Susan, Perez‐Olle, Raul, Fish‐Steagall, Ann, Kapoor, Kanika, Dharba, Sam, Lapuerta, Pablo, Benson, Al B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6853091/
https://www.ncbi.nlm.nih.gov/pubmed/31189618
http://dx.doi.org/10.1634/theoncologist.2018-0921

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6853091/
https://www.ncbi.nlm.nih.gov/pubmed/31189618
http://dx.doi.org/10.1634/theoncologist.2018-0921

Ejemplares similares